Nevertheless, a non-randomized multicenter phase 2 study using trametinib in combination with GSK2141795 (a pan AKT inhibitor) did not yield significant clinical activity in NRAS mutant melanomas [105]. This evidence concerns the gene AKT1 and melanoma.